PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib

Sorafenib is currently the only systemic agent approved for treatment of advanced hepatocellular carcinoma (HCC). However, intrinsic and acquired resistance to sorafenib remains a great challenge with respect to improving the prognoses of patients with HCC. The cyto-protective functions of autophagy...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Death Dis
Autors principals: Zhang, Kai, Chen, Jing, Zhou, Hao, Chen, Ying, Zhi, Yingru, Zhang, Bei, Chen, Longbang, Chu, Xiaoyuan, Wang, Rui, Zhang, Chunni
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833744/
https://ncbi.nlm.nih.gov/pubmed/29472524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-018-0344-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars